Maione V, Rovaris S, Romanó C, Bighetti S, Arisi M, Carrera C G, Bellinato F, Gisondi P, Fratton Z, Errichetti E, Bettolini L
Department of Dermatology, Spedali Civili, University of Brescia, Brescia, Italy.
Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Australas J Dermatol. 2025 Jun;66(4):215-219. doi: 10.1111/ajd.14467. Epub 2025 Apr 3.
HIV-positive patients with psoriasis often face delays in accessing biologic therapies due to their exclusion from clinical trials and concerns about the impact of immunomodulatory drugs on viral replication. Anti-IL-23 therapies, such as risankizumab and guselkumab, have shown great promise thanks to their strong efficacy and favourable safety profiles. A case series from four Italian centres reported sustained effectiveness of these drugs, with no observed effects on viral replication or immune parameters in HIV-positive patients. Although the number of cases is limited, these therapies appear to be a compelling option for patients with extensive or treatment-resistant psoriasis.
银屑病的HIV阳性患者常常因被排除在临床试验之外以及担心免疫调节药物对病毒复制的影响而在获得生物疗法方面面临延误。抗IL-23疗法，如司库奇尤单抗和古塞奇尤单抗，因其强大的疗效和良好的安全性而展现出巨大前景。来自四个意大利中心的病例系列报告了这些药物的持续有效性，在HIV阳性患者中未观察到对病毒复制或免疫参数的影响。尽管病例数量有限，但这些疗法似乎是广泛或治疗抵抗性银屑病患者的一个有吸引力的选择。
